Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 31, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Results presented virtually by Raymond Scott Turner, MD, PhD, support a larger, multi-center, phase 3 study to determine the safety and efficacy of nilotinib in patients with Alzheimer disease.
Tim Hagenacker, MD, describes spinal muscular atrophy as a very broad clinical spectrum disease, highlighting the various ways it can present in patients.
A trio of studies suggest that consistently vaccinations for influenza and pneumonia may reduce the incidence of Alzheimer later in life, as well as mortality for older adults.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jeffrey Cummings, MD, ScD, who discusses a recent review he and colleagues did of the trends in the Alzheimer Disease pipeline and what he expects for the future of the disease's care.
The findings indicate that the use of a MS severity score (Ped-MSSS) model may provide an alternative to EDSS scoring, which has been shown to be lower in pediatric disease, in clinical assessment of disease severity and disability accrual.